Center Laboratories (4123) - Total Assets
Based on the latest financial reports, Center Laboratories (4123) holds total assets worth NT$25.81 Billion TWD (≈ $813.14 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Center Laboratories (4123) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Center Laboratories - Total Assets Trend (2006–2024)
This chart illustrates how Center Laboratories's total assets have evolved over time, based on quarterly financial data. Check how high is Center Laboratories's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Center Laboratories - Asset Composition Analysis
Current Asset Composition (December 2024)
Center Laboratories's total assets of NT$25.81 Billion consist of 14.8% current assets and 85.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 5.7% |
| Accounts Receivable | NT$178.58 Million | 0.7% |
| Inventory | NT$309.70 Million | 1.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Center Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Center Laboratories (4123) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Center Laboratories's current assets represent 14.8% of total assets in 2024, a decrease from 57.5% in 2006.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 13.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 1.2% of total assets.
Center Laboratories Competitors by Total Assets
Key competitors of Center Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥39.93 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
Center Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.51 | 0.96 | 0.52 |
| Quick Ratio | 0.42 | 0.89 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-1.86 Billion | NT$-144.39 Million | NT$-1.32 Billion |
Center Laboratories - Advanced Valuation Insights
This section examines the relationship between Center Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | NT$25.54 Billion |
| Market Capitalization | $863.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Center Laboratories's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Center Laboratories's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Center Laboratories (2006–2024)
The table below shows the annual total assets of Center Laboratories from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$25.54 Billion ≈ $804.56 Million |
-5.43% |
| 2023-12-31 | NT$27.00 Billion ≈ $850.72 Million |
+7.20% |
| 2022-12-31 | NT$25.19 Billion ≈ $793.55 Million |
-17.26% |
| 2021-12-31 | NT$30.44 Billion ≈ $959.14 Million |
+9.25% |
| 2020-12-31 | NT$27.87 Billion ≈ $877.97 Million |
+21.87% |
| 2019-12-31 | NT$22.87 Billion ≈ $720.38 Million |
+12.21% |
| 2018-12-31 | NT$20.38 Billion ≈ $641.97 Million |
-46.80% |
| 2017-12-31 | NT$38.30 Billion ≈ $1.21 Billion |
+26.17% |
| 2016-12-31 | NT$30.35 Billion ≈ $956.35 Million |
+8.75% |
| 2015-12-31 | NT$27.91 Billion ≈ $879.41 Million |
+190.27% |
| 2014-12-31 | NT$9.62 Billion ≈ $302.96 Million |
+75.97% |
| 2013-12-31 | NT$5.46 Billion ≈ $172.17 Million |
+34.03% |
| 2012-12-31 | NT$4.08 Billion ≈ $128.45 Million |
+56.10% |
| 2011-12-31 | NT$2.61 Billion ≈ $82.29 Million |
+6.55% |
| 2010-12-31 | NT$2.45 Billion ≈ $77.23 Million |
+1.50% |
| 2009-12-31 | NT$2.42 Billion ≈ $76.09 Million |
+137.67% |
| 2008-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+56.62% |
| 2007-12-31 | NT$648.84 Million ≈ $20.44 Million |
+30.92% |
| 2006-12-31 | NT$495.58 Million ≈ $15.61 Million |
-- |
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more